Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus
Sarmad Said and German T. Hernandez
Affiliation: Division of Nephrology & Hypertension, Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, 4800 Alberta Avenue, El Paso, Texas, 79905, USA.
The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the
reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes
mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic
blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially
beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2
inhibitor approved for use in the United States.
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2
inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Rights & PermissionsPrintExport